<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Sunday, October 1, 2023</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| Genitourinary-Prostate NRG/RTOG 0415 | Title: Long-term follow-up analysis of NRG oncology RTOG 0415: a randomized phase III non-inferiority study comparing 2 fractionation schedules in patients with favorable-risk prostate cancer  
Presenter: W. Robert Lee, MD  
Abstract #: 6 | Location: San Diego Convention Center, Ballroom 20  
Session: CT 01: Clinical Trials Session  
Date: Sunday, October 1, 2023  
Time: 10:00AM – 10:10AM  
Duration: 10-min  
Oral Presentation |
| Prostate NRG/RTOG 0126 | Title: Long-Term Outcomes of NRG/RTOG 0126, A Randomized Trial of High Dose (79.2Gy) vs. Standard Dose (70.2Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer  
Presenter: Jeff Michalski, MD  
Abstract #: 7 | Location: Room 30 A/B/C  
Date: Sunday, October 1, 2023  
Time: 4:57PM - 5:17PM  
Master Class  
$25-Members/Nonmembers  
$0-Students/Residents/Fellows |
|  | **Beyond RTOGv2.0: The First Ten Years of NRG Oncology and Paying It Forward for Many Years Ahead**  
**Session Chairs:** Quynh Le, MD and Mitch Machtay  
**Speakers:** Kristin Higgins, MD and Vinai Gondi, MD | **Location:** Room 4  
**Session:** SS 07 - Bio 2: Genomics, Biomarkers, and Tumor Biology  
**Date:** Monday, October 2, 2023  
**Time:** 8:30AM-8:37AM  
**Duration:** 7-min  
**Oral Presentation** |
<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Monday, October 2, 2023</th>
<th>Time/Location</th>
</tr>
</thead>
</table>
| Genitourinary-Bladder NRG/RTOG 0524 NRG/RTOG 0712 | Title: Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation: analysis of NRG RTOG 0524 and 0712  
Presenter: Matthew Deek, MD  
Abstract #: 136 | Location: Room 6 C/F  
**Session:** SS 08 - GU 2: Clinical Trials in Prostate Cancer  
**Date:** Monday, October 2, 2023  
**Time:** 10:45AM - 10:52AM  
**Duration:** 7-min  
**Oral Presentation** |
| Genitourinary-Prostate NRG/RTOG 0534 | Title: Quality of life results of addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy: NRG Oncology/RTOG 0534 SPPORT  
Presenter: Deborah Bruner, MD  
Abstract #: 139 | Location: Room 7  
**Session:** OP 05 - H&N 1: Optimizing Patient-Centered Quality of Life and Function  
**Time:** 11:00AM - 11:05AM  
**Duration:** 5-min  
**Quick Pitch** |
| Head & Neck NRG/RTOG 1016 | Title: Hearing outcomes in cisplatin or cetuximab combined with radiation for patients with HPV-associated oropharyngeal cancer in NRG/RTOG 1016  
Presenter: Christina Runge, PhD  
Abstract #: 1052 | Location: Room 7  
**Session:** OP 05 - H&N 1: Optimizing Patient-Centered Quality of Life and Function  
**Time:** 11:00AM - 11:05AM  
**Duration:** 5-min  
**Quick Pitch** |
| Lung, Brain NRG-CC003 | Title: Primary endpoint results of NRG CC003: Phase II R/III trial of prophylactic cranial irradiation (PCI) with or without hippocampal avoidance (HA) for small cell lung cancer (SCLC)  
Presenter: Vinai Gondi, MD  
Abstract #: LBA 04 | Location: San Diego Convention Center, Ballroom 20  
**Session:** PL 01: Plenary Session  
**Date:** Monday, October 2, 2023  
**Time:** 1:30PM – 1:40PM  
**Duration:** 10-min  
**Plenary Session** |
<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Title</th>
<th>Location</th>
<th>Session</th>
<th>Date</th>
<th>Time</th>
<th>Duration</th>
<th>Oral Presentation</th>
</tr>
</thead>
</table>
| Genitourinary-Prostate NRG/RTOG 0521 | Title: Validation of a genomic classifier in the NRG Oncology/RTOG 0521 phase III trial of docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer.  
Presenter: Ryan Phillips, MD  
Abstract #: 158 | Room 6 D/E | SS 11-GU 3: Novel Prognostication Techniques for Prostate Cancer  
Date: Monday, October 2, 2023  
Time: 3:10PM – 3:17PM  
Duration: 7-min | Oral Presentation |
| Lung NRG/RTOG 0617, NRG-LU001 | Title: Progression-free survival as a surrogate endpoint of overall survival in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy: trial-level meta-analysis and individual-level analysis of NRG/RTOG 0617 and PROCLAIM  
Presenter: Chen Hu, PhD  
Abstract #: 1074 | Room 8 | Session: QP 07: Lung 2: Immune Checkpoint Inhibition (ICI): Incorporation into SOLC Management; Impacts on Toxicity for LA-NSCLC  
Date: Monday, October 2, 2023  
Time: 5:10PM - 5:15PM  
Duration: 5-min | Quick Pitch |
| Head & Neck NRG/RTOG 0920 | Title: Randomized phase III trial of postoperative radiotherapy with or without cetuximab for intermediate-risk squamous cell carcinoma of the head and neck (SCCHN): NRG/RTOG 0920  
Presenter: Mitchell Machtay, MD  
Abstract #: LBA 01 | San Diego Convention Center, Ballroom 20 | Session: PL 01: Plenary Session  
Date: Monday, October 2, 2023  
Time: 1:30PM - 3:00PM  
Duration: 10-min | Plenary Session |

**Tuesday, October 3, 2023**

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Title</th>
<th>Location</th>
<th>Session</th>
<th>Date</th>
<th>Time</th>
<th>Duration</th>
<th>Oral Presentation</th>
</tr>
</thead>
</table>
| Head & Neck NRG/RTOG 1016 | Title: The KRAS-variant and cetuximab in HPV-positive oropharyngeal cancer in NRG/RTOG 1016  
Presenter: Joanne Weidhaas, PhD  
Abstract #: 1172 | Room 4 | Session: OP 16 - H&N 3: Innovative Approaches to Individualizing Therapy for Head & Neck and Skin Cancer  
Date: Tuesday, October 3, 2023  
Time: 5:25PM - 5:30PM  
Duration: 5-min | Quick Pitch |
| Genitourinary-Prostate NRG/RTOG 0534 | Title: Impact of testosterone recovery on clinical outcomes of patients treated with salvage radiotherapy and androgen suppression: a secondary analysis of the NRG/RTOG 0534 SPPORT phase 3 trial  
Presenter: Alan Dal Pra, MD  
Abstract #: 261 | Room 6 B | Session: SS 28 - GU 4: Radiotherapy for Kidney Cancer and Post-Prostatectomy  
Date: Tuesday, October 3, 2023  
Time: 5:35PM – 5:42 PM  
Duration: 7-min | Oral Presentation |

The following presentations include NRG author/investigators from NCTN sponsored federal trials, and NSABP-RTOG-GOG Foundation studies

<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Title</th>
<th>Location</th>
<th>Session</th>
<th>Date</th>
<th>Time</th>
<th>Duration</th>
<th>Oral Presentation</th>
</tr>
</thead>
</table>
| Brain NRG-CC001 | Title: Estimation of Conditional Neurocognitive Function Failure (NCFF) Incidence in Patients Receiving Whole Brain Radiation Therapy (WBRT) for Brain Metastases (BM): Secondary Analysis of NRG CC001  
Presenter: Hua-Ren Cherng, MD  
Poster Bd #: 2208 | Hall B2 | Session: PQA 02 - Poster Q&A 02 - Central Nervous System and Palliative Care  
Date: Monday, October 2, 2023  
Time: 10:45AM – 12:00PM  
Duration: 75-min | Poster |
| Brain & Spine NRG/RTOG 9006 | Title: Conditional Survival Estimates for Malignant Glioma Patients by RPA Class: Secondary Analysis of RTOG 9006  
Presenter: Matthew Brown, MD  
Poster Bd #: 2200 | Hall B2 | Session: PQA 02 - Poster Q&A 02 - Central Nervous System and Palliative Care  
Date: Monday, October 2, 2023  
Time: 10:45AM – 12:00PM  
Duration: 75-min | Poster |
<table>
<thead>
<tr>
<th>Disease</th>
<th>Title</th>
<th>Presenter</th>
<th>Abstract #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>Conditional Risk and Predictive Factors Associated with Late Toxicity for Prostate Cancer Patients Treated with External Beam Radiotherapy Alone on Randomized Trial RTOG 0126</td>
<td>Gregory Alexander, MD</td>
<td>283</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>Effectiveness of Cisplatin in P16+ Oropharyngeal Cancer According to Relative Risk for Cancer Events: Ancillary Analysis of RTOG 1016</td>
<td>Loren Mell, MD, FASTRO</td>
<td>233</td>
</tr>
</tbody>
</table>